AGMBNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
AgomAb Therapeutics NV
Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 23, 2026
$8.23−0.05 (-0.60%)
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Apr 24, 2026 | After market close | – | – | – |
Press releases
Announcements AgomAb Therapeutics filed with the SEC
Agomab Announces First Patient Dosed in Global
EX-99.1 to Form 6-K
Agomab Announces Appointments of Marino Garcia
EX-99.1 to Form 6-K
Agomab Announces Proposed Appointments of Marino
EX-99.1 to Form 6-K
Invitation to the special and extraordinary
EX-99.2 to Form 6-K
Naamloze vennootschap / Limited liability company
EX-99.3 to Form 6-K
Agomab Reports Half Year 2026 Financial Results and Confirms 2026 Outlook
EX-99.1 to Form 6-K
Announces Results of Annual General Meeting
EX-99.1 to Form 6-K
Reports Full Year 2025 Financial Results and Confirms 2026 Outlook
EX-99.1 to Form 6-K
annual general meeting on May 26, 2026
EX-99.2 to Form 6-K
Naamloze vennootschap / Limited liability company
EX-99.3 to Form 6-K
Agomab Announces Launch of Initial Public Offering
EX-99.1 to Form 6-K
Agomab Announces Pricing of Initial Public Offering
EX-99.2 to Form 6-K
Agomab Announces Closing of Initial Public Offering
EX-99.3 to Form 6-K